An antibiotic can remain biologically active after it leaves the production line in wastewater or solid waste. If those residues reach the environment without adequate control, they can create conditions that favour resistant bacteria. For pharmaceutical manufacturers, the environmental performance of a medicine therefore extends through its waste streams and treatment arrangements. [1]
World AMR Awareness Week 2026, observed from 18–24 November, brings this responsibility into focus through the theme “One Health, one action: Prevent AMR now”. The campaign connects the health of people, animals, plants and the environment. [2]
For Indian active pharmaceutical ingredient (API) manufacturers, formulation companies and their buyers, the practical question is whether antibiotic losses are understood and controlled. This article examines the applicable requirements, the ESG risks and the evidence that supports responsible sourcing.
At a glance
Antibiotic residues need assessment alongside conventional wastewater parameters.
Indian discharge requirements, scientific guidance and procurement conditions have different roles.
Supplier checks should follow production, treatment and the final destination of contaminated waste.
Improvement plans need named owners, verified results and deadlines for correcting gaps.
How antibiotic pollution contributes to resistance
Antibiotic resistance develops in bacteria. Exposure can give resistant organisms a survival or growth advantage over more susceptible bacteria, allowing resistance traits to become more common. Some resistance genes can also move between bacteria. Selection can occur at concentrations below those needed to stop bacterial growth, which makes the concentration and identity of a residue relevant to environmental assessment. [3]
Manufacturing is one source of antibiotics entering the environment, alongside pathways associated with their use. WHO identifies manufacturing emissions as a particular concern for the emergence of new resistance. This supports preventive controls; it does not establish what proportion of infections in a community was caused by a particular factory. [4]
The assessment must follow the material. Process wastewater, equipment washings, fermentation residues and treatment sludge may require different controls. An antibiotic removed from a liquid stream may need further management in the material that retains it. WHO’s manufacturing guidance covers wastewater and solid waste across API production, formulation and primary packaging. [1]
For a business, this changes the evidence required. A general statement about water recycling leaves unanswered which antibiotic was present, where it went and whether the relevant treatment worked.
Which effluent rules and manufacturing standards apply in India?
Indian requirements start with the site and discharge route
The pharmaceutical effluent standards notified through G.S.R. 541(E) on 6 August 2021 include pH, biochemical oxygen demand (BOD), chemical oxygen demand (COD), suspended solids and a bioassay test. The final notification did not include the individual antibiotic-residue limits proposed in the 2020 draft. Applicable requirements also depend on the discharge route and conditions imposed by the pollution control authorities. [5][6]
CPCB’s API-residue monitoring guidance identifies predicted no-effect concentrations, or PNECs, as reference limits for self-monitoring in the absence of national antibiotic-residue standards. It addresses monitoring at manufacturing units, common effluent treatment plants and receiving environments. A site should maintain a clear register of its consent conditions, monitoring obligations and applicable waste requirements. [7]
Zero liquid discharge (ZLD) requires the same care over applicability. A March 2026 parliamentary reply states that CPCB has not made ZLD mandatory for all industrial units. The requirement for an individual factory must be checked against its approvals and applicable directions. [8]
WHO guidance supplies a technical basis for control
WHO’s September 2024 manufacturing guidance provides a scientific basis for managing antibiotic emissions, with risk management, verification and transparency as central elements. It is guidance rather than a universally binding discharge law; regulators and purchasers can incorporate its provisions into their own requirements. [9][4]
A PNEC is a substance-specific risk benchmark. Targets addressing resistance selection and aquatic ecological effects answer different questions. The chosen value, assessment method and point of comparison should therefore be documented. A concentration target needs its scientific context and does not guarantee that every environmental risk has disappeared. [3]
Industry standards and certification address buyer assurance
The AMR Industry Alliance updated its Antibiotic Manufacturing Standard in May 2025 and has published a 2026 update to its PNEC tables. Companies should check the current reference values when reviewing their assessment. [10][11]
BSI’s Kitemark programme for minimised AMR risk began transitioning to the May 2025 standard from 1 January 2026. It offers independent assessment of manufacturing controls intended to manage antibiotic waste discharges. Certification is voluntary, although a procurement programme or contract can require particular evidence. [10][12]

Where the ESG risks reach the business
The environmental issue is the release and movement of active residues through water and waste. The social concern includes the potential contribution to resistance and the implications for people who depend on the surrounding environment. Governance determines whether someone identifies a problem, authorises corrective spending and verifies the result. WHO’s guidance connects these responsibilities through risk management, independent scrutiny and public transparency. [9]
Operational compliance also needs continuing attention. The March 2026 parliamentary reply covering pharmaceutical and chemical units in Dadra and Nagar Haveli and Daman and Diu recorded notices for violations including effluent or emission exceedances, non-operation of treatment plants and improper hazardous-waste handling, despite valid authorisations. A permit and evidence of day-to-day performance serve different purposes. [8]
Commercial exposure becomes more direct when environmental evidence affects procurement eligibility. NHS England’s Antimicrobial Products Subscription Model requires independent assessment against specified antibiotic manufacturing standards addressing resistance and ecotoxicity. This is a concrete purchasing example whose conditions apply to that scheme; buyers and procurement programmes set their own requirements. [13]
For an Indian supplier, the practical implication is to establish those expectations before quoting or renewing a contract. If the required evidence concerns an upstream API plant, a questionnaire completed only by the finished-product supplier leaves a gap. Supplier due diligence should identify who can provide the information and who has authority to resolve deficiencies.
What should buyers check at manufacturing sites?
The AMR Industry Alliance standard provides informative supplier-audit guidance. Assessments can use appropriate mass-balance calculations or chemical measurements, subject to the method’s conditions. [14]
The following questions connect manufacturing records, monitoring and waste-contractor oversight:
|
Audit question |
Evidence to request |
|---|---|
|
Which site makes the antibiotic being purchased? |
Product-to-site mapping, process description and the boundary of the assessment. |
|
Where can antibiotic material leave the process? |
Waste-flow records covering wastewater, solids, storage and external treatment or disposal. |
|
What target is used, and where? |
The selected compound-specific benchmark, its version and the basis for the comparison. |
|
Do the results represent actual operations? |
Production dates, assessment assumptions, sampling records, laboratory methods and relevant treatment evidence. |
|
What happens when controls fail? |
Incident records, corrective actions, accountable owners and evidence that the problem was resolved. |
External waste services belong in this review. The Pharmaceutical Supply Chain Initiative (PSCI) includes questions about selecting and managing third-party waste facilities and documenting disposal methods and destinations. PSCI supplies an assessment framework; it is not a certification body. [15]
Teams preparing for an ESG audit should organise the evidence so that a reviewer can trace a finding back to the production period, waste stream and responsible person. An unexplained spreadsheet total offers little help when the underlying process has changed.
How manufacturers can strengthen antibiotic pollution controls
Map losses and prioritise the gaps
Start with an inventory of antibiotics handled, the quantities involved and the routes through which losses can occur. Record where treatment happens and who manages residual waste. Use this information when assessing supplier ESG risks, so that purchasing teams can prioritise missing information, weak controls and critical supply dependencies.
Potential controls include process improvements and separate handling of concentrated rinses, subject to pharmaceutical quality requirements. [14]
Verify performance under representative conditions
WHO’s accompanying FAQ calls for assessment of peak emissions rather than averages and chemical analysis when claiming antibiotic removal during wastewater treatment. It also requires chemical analysis for fermentation-based production. The monitoring plan should reflect those requirements where the WHO approach is being used. [4]
BOD and COD describe aspects of wastewater pollution, but they do not identify the concentration of an individual antibiotic. The practical implication of compound-specific assessment is that acceptable general effluent results need supporting evidence about the relevant residues. Laboratory reporting limits also need to be low enough to evaluate the chosen target; “not detected” is only informative when the method is sufficiently sensitive. [5][7]
Follow residues through treatment and disposal
For ZLD operations, WHO highlights risks from releases to land and soil and from solid-waste storage runoff. Water recovery therefore needs to be considered alongside the management of concentrates, sludge and other residual material. [4]
Check the capabilities of external treatment and disposal partners and retain records of what they receive and how it is managed. This follows PSCI’s emphasis on waste-service oversight. Companies can explore OneStop ESG’s water and wastewater treatment providers, then assess shortlisted providers against their antibiotic profile, waste streams and monitoring needs. [15]
Make the findings part of management decisions
Assign each improvement a budget, owner and completion date. Useful management measures include the proportion of relevant production covered by an assessment, unresolved exceedances, overdue corrective actions and gaps in contractor evidence. Define the denominator and period so that the figures can be compared meaningfully.
Procurement and operations should agree how deficiencies will be addressed, including interim controls and verification. WHO advocates progressive improvement that also considers access, affordability and continuity of antibiotic supply. This supports a planned response to identified risks, with clear conditions for continued sourcing. [9]
.png?alt=media&token=ac5c12ee-c5da-4c97-8e29-4d32678ac83a)
Common mistakes that weaken pharma effluent management
-
Treating general effluent results as a complete assessment. Include evidence about the specific antibiotics handled and the relevant waste routes.
-
Relying on a ZLD label. Verify water recovery, residual-waste management and the actual operating arrangements.
-
Using an old benchmark without checking revisions. Record the source and version, and revisit affected assessments when values change.
-
Stopping at the direct supplier. Identify the manufacturing site and the external facilities handling its antibiotic-containing waste.
-
Closing an audit finding when equipment is purchased. Closure should follow evidence that the agreed control works under the relevant operating conditions.
Conclusion
Responsible antibiotic manufacturing requires a traceable account of what enters the waste system, how it is controlled and where the remaining material goes. For Indian manufacturers and their buyers, World AMR Awareness Week 2026 is an opportunity to connect that evidence with operating budgets, supplier decisions and corrective action. The immediate task is to identify the weakest part of that chain and assign responsibility for improving it.
Frequently asked questions
What is antibiotic pollution from pharmaceutical manufacturing?
It is the release of antibiotic substances from manufacturing activities into the environment, including through wastewater or inadequately managed solid waste. Their biological activity can create resistance-selection and ecological risks, which is why assessment needs to consider the specific compounds and release pathways. [1]
Do BOD and COD results show whether antibiotics are controlled?
They provide information about general wastewater characteristics. Evaluating antibiotic residues requires an assessment relevant to the compounds involved, using suitable methods and benchmarks. A laboratory method must be capable of evaluating the concentration target being used. [5][7]
Is zero liquid discharge mandatory for every Indian pharma factory?
A March 2026 parliamentary reply states that CPCB has not made ZLD mandatory for all industrial units. Each factory must check its own consent conditions and applicable directions. Where ZLD applies, operating evidence and residual-waste controls still need review. [8]
What does a PNEC mean for antibiotic wastewater?
A predicted no-effect concentration is a scientific benchmark used to assess risk. Antibiotic assessments can consider resistance selection and ecological effects. The value is specific to the substance and endpoint, with uncertainties addressed through its derivation; it is not automatically a statutory discharge limit. [3][7]
Does AMR certification cover every product a company makes?
Certification concerns specified antibiotics at a particular manufacturing location. Buyers should check the certificate’s product coverage, site, standard version and validity. It does not assess every company activity or environmental impact. [14]
Source record
Sources checked on 18 November 2026. The 2026 campaign, PNEC update and parliamentary reply are used alongside the current identified manufacturing standard and the applicable earlier guidance and legal text. Publication dates are retained accurately.
[1] World Health Organization. New global guidance aims to curb antibiotic pollution from manufacturing
[2] World Health Organization. World AMR Awareness Week 2026
[3] World Health Organization. Evidence synthesis for deriving PNECs for resistance selection
[4] World Health Organization. Frequently asked questions accompanying the manufacturing guidance
[5] Ministry of Environment, Forest and Climate Change; official Odisha PCB copy. G.S.R. 541(E), Environment (Protection) Second Amendment Rules, 2021
[6] Supreme Court of India. Order in Civil Appeal Diary 25732/2022
[7] Central Pollution Control Board. Guidelines on Monitoring Mechanism for API Residue
[8] Press Information Bureau / Department of Pharmaceuticals. Red Category Pharmaceutical Units
[9] World Health Organization. Guidance on wastewater and solid waste management for manufacturing of antibiotics
[10] AMR Industry Alliance. Responsible Manufacturing
[11] AMR Industry Alliance. 2026 Changes to the PNEC Table
[12] BSI. BSI Kitemark for Minimized Risk of AMR
[13] NHS England. Antimicrobial Products Subscription Model: guidance on commercial arrangements
[14] AMR Industry Alliance. Antibiotic Manufacturing Standard
[15] Pharmaceutical Supply Chain Initiative. PSCI principles and audit-question mapping





.png%3Falt%3Dmedia%26token%3Db068dc33-4764-4d57-a516-d75b75ceaba3&w=1920&q=90)
